Cognition Therapeutics, Inc. (NASDAQ:CGTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the four ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating and three have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $3.33.
Several analysts have recently weighed in on CGTX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Monday, September 21st. Wall Street Zen downgraded Cognition Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, HC Wainwright restated a “buy” rating on shares of Cognition Therapeutics in a research note on Monday, October 5th.
Get Our Latest Stock Report on Cognition Therapeutics
Institutional Investors Weigh In On Cognition Therapeutics
Large investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Cognition Therapeutics in the second quarter valued at approximately $1,451,000. Tocqueville Asset Management L.P. purchased a new position in shares of Cognition Therapeutics during the second quarter worth approximately $369,000. Renaissance Technologies LLC increased its holdings in shares of Cognition Therapeutics by 15.2% in the 1st quarter. Renaissance Technologies LLC now owns 1,117,136 shares of the company’s stock valued at $848,000 after acquiring an additional 147,623 shares during the period. Texas Capital Bank Wealth Management Services Inc acquired a new position in shares of Cognition Therapeutics in the 2nd quarter valued at $165,000. Finally, Sigma Planning Corp increased its holdings in shares of Cognition Therapeutics by 56.3% in the 1st quarter. Sigma Planning Corp now owns 337,765 shares of the company’s stock valued at $257,000 after acquiring an additional 121,600 shares during the period. 43.35% of the stock is owned by institutional investors and hedge funds.
Cognition Therapeutics Price Performance
Shares of CGTX opened at $0.73 on Tuesday. Cognition Therapeutics has a 1-year low of $0.55 and a 1-year high of $1.93. The firm has a fifty day moving average price of $0.96 and a 200 day moving average price of $1.07.
Cognition Therapeutics (NASDAQ:CGTX – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. As a group, equities analysts expect that Cognition Therapeutics will post -0.30 EPS for the current fiscal year.
About Cognition Therapeutics
Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for neurodegenerative diseases that affect memory, cognition and behavior. The company’s research centers on drug candidates designed to protect or restore synaptic function, which is important for communication between nerve cells.
Cognition Therapeutics’ lead investigational product is CT1812, an orally administered, brain-penetrant small molecule designed to modulate the sigma-2 receptor complex.
See Also
- Five stocks we like better than Cognition Therapeutics
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for Cognition Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognition Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
